Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...

Eli Lilly & Co plans to invest £279 million ($364 million) in a new initiative to support UK biotechs along with a study of ...

PepsiCo and other snack stocks are suffering as households cut costs. Why tiny Utz Brands looks like a better buy.

Zealand Pharma's CEO Adam Steensberg weighs in on early-stage trials of its obesity drug contender and talks down takeover ...

Medicare is prohibited by law from covering GLP-1 drugs for weight loss. But many beneficiaries can access the drugs anyway.

Only a fifth of large U.S. companies cover pricey GLP-1 weight-loss drugs like Wegovy and Zepbound in their health insurance ...

When it comes to coverage for the pricey GLP-1 weight-loss drugs Wegovy and Zepbound, only a fifth of large U.S. com ...

The Portuguese Association for the Protection of Diabetics (APDP) has defended the extension of the co-payment for type 2 ...

Allowing Medicare to cover anti-obesity medications would drive up federal spending by about $35 billion on net between 2026 and 2034, according to ...

Regeneron's CSO George Yancopoulos warns that GLP-1 weight-loss drugs like Ozempic may lead to rapid muscle loss, increasing ...

Authorizing Medicare to cover weight loss drugs would increase federal spending by about $35 billion from 2026 to 2034 ...

The cost of taking weekly injections of popular anti-obesity medications liraglutide (Saxenda) or semaglutide (Wegovy) ...